57.97
  Price1.46%   -0.86
(Pre-market: 58.67 +0.70 +1.21%)
May-16-22 09:40AM Is Galapagos (GLPG) Outperforming Other Medical Stocks This Year?Zacks Investment Research
May-11-22 09:47AM Perrigo (PRGO) Q1 Earnings Miss, Margins Hurt by Higher CostsZacks Investment Research
May-09-22 03:30AM RBC Expects Business Development To Unlock This Pharma Stock's Balance Sheet ValueBenzinga
May-06-22 04:01AM Galapagos creëert nieuwe inschrijvingsrechtenplannen  GlobeNewswire Inc.
May-05-22 08:43AM The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder StudyBenzinga
Apr-28-22 09:40AM Has Galapagos (GLPG) Outpaced Other Medical Stocks This Year?Zacks Investment Research
Apr-04-22 09:10AM Strength Seen in Galapagos NV (GLPG): Can Its 5% Jump Turn into More Strength?Zacks Investment Research
Mar-28-22 02:01AM Jyseleca® goedgekeurd voor colitis ulcerosa in JapanGlobeNewswire Inc.
Mar-24-22 04:17AM Correction: Galapagos publiceert 2021 jaarverslag en kondigt buitengewone en jaarlijkse aandeelhoudersvergaderingen aanGlobeNewswire Inc.
04:01AM Galapagos publiceert 2021 jaarverslag en kondigt buitengewone en jaarlijkse aandeelhoudersvergaderingen aanGlobeNewswire Inc.
Mar-18-22 05:01AM Galapagos increases share capital through subscription right exercisesGlobeNewswire Inc.
Feb-28-22 12:33PM Tracking David Einhorn's Greenlight Capital Portfolio - Q4 2021 UpdateSeeking Alpha
Feb-24-22 04:01AM Galapagos 2021 results set stage for future growthGlobeNewswire Inc.
Feb-17-22 08:00AM The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For AgiosBenzinga
Feb-13-22 08:32AM The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And MoreBenzinga
Feb-03-22 04:01AM Galapagos receives transparency notification from EcoR1 CapitalGlobeNewswire Inc.
Feb-02-22 04:01AM Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohn’s and Colitis Organization (ECCO) annual congress GlobeNewswire Inc.
Jan-27-22 07:57AM The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster StudyBenzinga
Jan-26-22 04:40AM Galapagos creëert nieuw inschrijvingsrechtenplanGlobeNewswire Inc.
04:01AM Galapagos benoemt Paul Stoffels tot Chief Executive OfficerGlobeNewswire Inc.
Jan-19-22 07:40AM The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive DataBenzinga
Jan-18-22 04:01AM JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN    GlobeNewswire Inc.
Jan-13-22 04:01AM Galapagos creëert nieuw inschrijvingsrechtenplanGlobeNewswire Inc.
Jan-06-22 09:30AM Galapagos to present at 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire Inc.
Dec-03-21 04:01AM Galapagos increases share capital through subscription right exercisesGlobeNewswire Inc.
Nov-22-21 04:01AM Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney diseaseGlobeNewswire Inc.
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
Cap:    |  Volume (24h):